Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sanguinarium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 4/20 | 0.97 |
| ▸ | BCHE known ✓ | P06276 | 3/20 | 0.97 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.63 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.63 |
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 0.62 |
| ▸ | BAD | Q92934 | 7/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.97 |
| ▸ | MAPT | P10636 | 6/20 | 0.97 |
| ▸ | HPGD | P15428 | 6/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.97 |
| ▸ | MEN1 | O00255 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 4/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.97 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sanguinarium SCHEMBL23524622 | 0.99 | BAD (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL29385229 | 0.99 | BAD (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL30129850 | 0.99 | BAD (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL30153784 | 0.99 | BAD (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL123241 | 0.99 | BAD (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL43290 | 0.97 | RAC1 (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL30668087 | 0.97 | RAC1 (1.00) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL8584009 | 0.97 | BAD (0.97) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL3222766 | 0.96 | RAC1 (0.97) | BADALDH1A1MAPTHPGDSMN1; SMN2 | |
| Sanguinarium SCHEMBL8583232 | 0.96 | RAC1 (0.97) | BADALDH1A1MAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0671930-A4 | PROPHYLAXIS AND TREATMENT OF ADVERSE ORAL CONDITIONS WITH BIOLOGICALLY ACTIVE PEPTIDES. | MAGAININ PHARMA (US) | 1996-02-07 | — | — | EP | claimed |
| EP-0671930-A1 | PROPHYLAXIS AND TREATMENT OF ADVERSE ORAL CONDITIONS WITH BIOLOGICALLY ACTIVE PEPTIDES | MAGAININ PHARMACEUTICALS INC. (US) | 1995-09-20 | — | — | EP | claimed |
| WO-1993001723-A1 | PROPHYLAXIS AND TREATMENT OF ADVERSE ORAL CONDITIONS WITH BIOLOGICALLY ACTIVE PEPTIDES | MAGAININ PHARMACEUTICALS, INC. (US) | 1993-02-04 | — | — | WO | claimed |
| EP-0671930-A4 | PROPHYLAXIS AND TREATMENT OF ADVERSE ORAL CONDITIONS WITH BIOLOGICALLY ACTIVE PEPTIDES. | MAGAININ PHARMA (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0671930-A1 | PROPHYLAXIS AND TREATMENT OF ADVERSE ORAL CONDITIONS WITH BIOLOGICALLY ACTIVE PEPTIDES | MAGAININ PHARMACEUTICALS INC. (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1993001723-A1 | PROPHYLAXIS AND TREATMENT OF ADVERSE ORAL CONDITIONS WITH BIOLOGICALLY ACTIVE PEPTIDES | MAGAININ PHARMACEUTICALS, INC. (US) | 1993-02-04 | — | — | WO | disclosed |